Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label linaclotide safety in pediatric functional constipation and IBS-C
2019-001955-38Phase 3Terminated
- Sponsor
- Allergan
- Start
- Mar 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of linaclotide in functional constipation (FC) and irritable bowel syndrome (IBS) (2 cohorts), sponsored by Allergan. Primary endpoint: Long-term safety of linaclotide. Started Mar 2021; status: terminated.
02
Drugs
linaclotide
03
Conditions
functional constipation (FC)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2019-001955-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001955-38.